Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Spruce Biosciences (SPRB) EBITDA Margin (2023 - 2024)

Spruce Biosciences (SPRB) has disclosed EBITDA Margin for 2 consecutive years, with 3313.5% as the latest value for Q4 2024.

  • On a quarterly basis, EBITDA Margin fell 296896.0% to 3313.5% in Q4 2024 year-over-year; TTM through Sep 2025 was 6887.76%, a 633148.0% decrease, with the full-year FY2024 number at 1079.94%, down 61051.0% from a year prior.
  • EBITDA Margin was 3313.5% for Q4 2024 at Spruce Biosciences, down from 1445.17% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 344.54% in Q4 2023 to a low of 3313.5% in Q4 2024.